Publications on vidutolimod (CMP-001)

  1. Lemke-Miltner, C.D., et al. Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization. J Immunol, 2020. 204(5): 1386-1394.  
  1. Cheng Y., et al. In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. J Immunother Cancer, 2020. 8(2).   
  1. Younes A.I., et al. Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity. Transl Oncol, 2021. 14(2): 100983.  
  1. Miller, A.M., et al. Intraperitoneal CMP-001: a novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer. Ann Surg Onc, 2021. 28 (2): 1187-1197. 
  1. Sabree, S.A., et al. Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. J Immunother Cancer, 2021. 9 (6).  
  1. Ribas, A., et al. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov, 2021. 0425.20.  
  1. Sabree, S.A., et al. Monocytes Exposed to Immune Complexes Reduce pDC Type 1 Interferon Response to Vidutolimod. Vaccines (Basel), 2021. 9 (9): 982.  

Review Articles – pDC

  1. Lombardi, V.C., et al. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression. Eur J Clin Invest, 2015. 45: 1-8.
  2. Di Domizio, J., et al. Plasmacytoid dendritic cells in melanoma: can we revert bad into good?. J Invest Dermatol, 2014. 134(7): 1797-1800.
  3. Demoulin, S., et al. Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms. J Leukoc Biol, 2013. 93(3): 343-352.

Patient Resources

Melanoma Research Alliance

National Cancer Institute

American Cancer Society

Head and Neck Cancer Alliance

American Melanoma Foundation